ホーム › 骨髄異形成症候群 › ワシントン › Seattle
Seattle、WAにおける骨髄異形成症候群の臨床試験
Seattleとその周辺地域（約30マイル以内）の拠点で、骨髄異形成症候群に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Swedish Medical Center-First Hill, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
被験者募集中第1/2相
- University of Washington, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
被験者募集中第1相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
被験者募集中観察研究
- Fred Hutchinson, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
被験者募集中第2相健康なボランティア歓迎
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
被験者募集中第1相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
被験者募集中第1/2相健康なボランティア歓迎
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
被験者募集中第2/3相
- Seattle Cancer Care Alliance, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
被験者募集中第2相
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
他の都市における骨髄異形成症候群の試験
- Houston, TX43件の研究
- Baldwin Park, CA26件の研究
- New York City, NY21件の研究
- Washington, DC20件の研究
- Boston, MA19件の研究
- Tampa, FL19件の研究
- Miami, FL17件の研究
- Columbus, OH14件の研究
- Durham, NC14件の研究
- Chicago, IL13件の研究
- Atlanta, GA13件の研究
- St. Louis, MO13件の研究
Seattleにおける他の研究
- 非小細胞肺癌53件の研究
- がん（全種類）49件の研究
- 前立腺がん42件の研究
- 急性骨髄性白血病40件の研究
- 乳がん39件の研究
- 転移性癌39件の研究
- 大腸癌34件の研究
- 肺がん33件の研究
- 卵巣がん30件の研究
- 多発性骨髄腫22件の研究
- 急性リンパ性白血病21件の研究
- 膀胱癌21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。